Improved outcome of patients with low- and intermediate-risk cytogenetics acute myeloid leukemia (AML) in first relapse with gemtuzumab and cytarabine versus cytarabine: Results of a retrospective comparative study

Cancer

Volumn 117, Issue 5, 2011, Pages 974-981

  Prebet, Thomas ^a,b   Etienne, Anne ^a,b   Devillier, Raynier ^a   Romeo, Emilie ^a,c   Charbonnier, Aude ^a   D'Incan, Evelyne ^a   Esterni, Benjamin ^a   Arnoulet, Christine ^a   Blaise, Didier ^a,b   Vey, Norbert ^a,b  

^a INSTITUT PAOLI CALMETTES   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c Onco hematology Service   (France)

Author keywords

Acute myeloid leukemia; Cytarabine; Gemtuzumab ozogamycin; Relapse

Indexed keywords

ANTHRACYCLINE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GEMTUZUMAB; MERCAPTOPURINE; METHOTREXATE; MITOXANTRONE; TOPOTECAN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CONTROLLED STUDY; CYTOGENETICS; DRUG EFFICACY; DRUG MEGADOSE; FOLLOW UP; HUMAN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MONOTHERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; TREATMENT RESPONSE; VEIN OCCLUSION;

ADULT; AGED; AMINOGLYCOSIDES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; CYTOGENETIC ANALYSIS; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, MYELOID, ACUTE; MIDDLE AGED; NEOPLASM STAGING; RECURRENCE; RETROSPECTIVE STUDIES; RISK; SALVAGE THERAPY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79952020383     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25554     Document Type: Article

References (27)

1. Vey N, Keating M, Giles F, Cortes J, Beran M, Estey E. Effect of complete remission on survival in patients with acute myelogenous leukemia receiving first salvage therapy. Blood. 1999;93:3149-3150. (Pubitemid 29200811)
2. Breems DA, Van Putten WL, Huijgens PC, et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol. 2005;23:1969-1978. (Pubitemid 46211376)
3. Estey EH. Treatment of relapsed and refractory acute myelogenous leukemia. Leukemia. 2000;14:476-479. (Pubitemid 30142875)
4. Craddock C, Tauro S, Moss P, Grimwade D. Biology and management of relapsed acute myeloid leukaemia. Br J Haematol. 2005;129:18-34. (Pubitemid 40524048)
5. Herzig RH, Lazarus HM, Wolff SN, Phillips GL, Herzig GP. High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia. J Clin Oncol. 1985;3:992-997. (Pubitemid 15028571)
6. Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115:453-474.
7. Sievers EL, Larson RA, Stadtmauer EA, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001;19:3244-3254. (Pubitemid 32591442)
8. Amadori S, Suciu S, Selleslag D, et al. Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19). Br J Haematol. 2010;149:376-382.
9. Chevallier P, Delaunay J, Turlure P, et al. Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia. J Clin Oncol. 2008;26:5192-5197.
10. Tsimberidou A, Estey E, Cortes J, et al. Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes. Cancer. 2003;97:1481-1487. (Pubitemid 36297778)
11. Arceci RJ, Sande J, Lange B, et al. Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia. Blood. 2005;106:1183-1188. (Pubitemid 41129576)
12. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937-951.
13. Dastugue N, Payen C, Lafage-Pochitaloff M, et al. Prognostic significance of karyotype in de novo adult acute myeloid leukemia. The BGMT group. Leukemia. 1995;9:1491-1498.
14. Amadori S, Arcese W, Isacchi G, et al. Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia. J Clin Oncol. 1991;9:1210-1214.
15. Chevallier P, Roland V, Mahe B, et al. Administration of mylotarg 4 days after beginning of a chemotherapy including intermediate-dose aracytin and mitoxantrone (MIDAM regimen) produces a high rate of complete hematologic remission in patients with CD33+ primary resistant or relapsed acute myeloid leukemia. Leuk Res. 2005;29:1003-1007. (Pubitemid 40982594)
16. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21:4642-4649. (Pubitemid 46594039)
17. Kantarjian H, O'Brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer. 2006;106:1090-1098.
18. Litzow MR, Othus M, Cripe LD, et al. Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group. Br J Haematol. 2010;148:217-225.
19. Martin MG, Augustin KM, Uy GL, et al. Salvage therapy for acute myeloid leukemia with fludarabine, cytarabine, and idarubicin with or without gemtuzumab ozogamicin and with concurrent or sequential G-CSF. Am J Hematol. 2009;84:733-737.
20. Giles F, Vey N, DeAngelo D, et al. Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse. Blood. 2009;114:4027-4033.
21. Faderl S, Ferrajoli A, Wierda W, et al. Clofarabine combinations as acute myeloid leukemia salvage therapy. Cancer. 2008;113:2090-2096.
22. Burnett A, Hills R, Milligan D, et al. Attempts to optimise induction and consolidation chemotherapy in patients with acute myeloid leukaemia: results of the MRC AML15 Trial. Blood. 2009;114:484.
23. Delaunay J, Vey N, Leblanc T, et al. Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup. Blood. 2003;102:462-469.
24. Borthakur G, Faderl S, Verstovsek S, et al. Clinical and Molecular Response in Core Binding Factor Acute Myelogenous Leukemia with Fludarabine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin. Blood. 2009;114:2056.
25. Clavio M, Vignolo L, Albarello A, et al. Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and comparison with a historical cohort of patients. Br J Haematol. 2007;138:186-195. (Pubitemid 46976329)
26. Tanaka M, Kano Y, Akutsu M, et al. The cytotoxic effects of gemtuzumab ozogamicin (mylotarg) in combination with conventional antileukemic agents by isobologram analysis in vitro. Anticancer Res. 2009;29:4589-4596.
27. Chevallier P, Prebet T, Turlure P, et al. Prior treatment with gemtuzumab ozogamicin and the risk of veno-occlusive disease after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplant. 2009;45:165-170.